Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia

Abstract

A composition for use in a human by oral administration to reduce or control cardiometabolic risk factors associated with metabolic syndrome or hypercholesterolemia, or reduce risk of developing metabolic syndrome or hypercholesterolemia. The composition includes a combination of Arabinogalactan and Dihydroquercetin (taxifolin), where the Arabinogalactan is present in the combination as a fiber matrix in an amount higher than 70% as determined by weight on dry matter basis, and the Dihydroquercetin is present in the fiber matrix.

What is claimed is: 
     
         1 . A composition for use in a human by oral administration to reduce or control cardiometabolic risk factors associated with metabolic syndrome or hypercholesterolemia, or reduce risk of developing metabolic syndrome or hypercholesterolemia, said composition comprising a combination of Arabinogalactan and Dihydroquercetin (taxifolin), wherein said Arabinogalactan is present in said combination as a fiber matrix in an amount higher than 70% as determined by weight on thy matter basis and said Dihydroquercetin is present in said fiber matrix. 
     
     
         2 . A composition for use according to  claim 1  wherein metabolic syndrome in a human is defined by at least three characteristics selected from:
 (a) a waist circumference greater than 102 cm for men and greater than 88 cm for women, 
 (b) a triglyceride level greater than 150 mg/dl, 
 (c) an HDL-cholesterol level less than 40 mg/dl for men and less than 50 mg/dl for women, 
 (d) a blood pressure greater than or equal to 130/85 mmHG, and 
 (e) a fasting glucose level greater than 110 mg/dl. 
 
     
     
         3 . A composition for use according to  claim 1  wherein said Arabinogalactan fiber matrix containing Dihydroquercetin is derived from a hardwood or coniferous wood of a  Larix  species and wherein said Arabinogalactan is Larch Arabinogalactan. 
     
     
         4 . A composition for use according to  claim 3  wherein one gram of said Arabinogalactan has a capacity to inhibit lipid oxidation equivalent to at least 1.000 μmol Trolox Equivalent (TE)/gram based on an. Oxygen Radical Absorbance Capacity (ORAC) value, wherein one gram of said Arabinogalactan has an antioxidant capacity of Cell-based Antioxidant Protection (CAP-e) to protect live cells from oxidative damage to at least 6 CAP-e units per grain, where the CAP-e value is in Gallic Acid Equivalent (GAE) units; and wherein said antioxidant capacity is derived from natural constituents of said combination of said Arabinogalactan and said Dihydroquercetin but not from added antioxidants. 
     
     
         5 . A composition for use according to  claim 1  wherein said composition is a nutraceutical composition. 
     
     
         6 . A composition for use according to  claim 1  wherein said composition is a beverage. 
     
     
         7 . A composition for use according to  claim 1  wherein said composition is a nutritional bar. 
     
     
         8 . A composition for use according to  claim 1  wherein said composition is in a form of a tablet, a pill, a granule, a dragee, a capsule or an effervescent formulation. 
     
     
         9 . A composition for use in a human by oral administration to provide support in said human in reducing and controlling detrimental effects caused by poor diet whereby said administration increases short-chain fatty acids, decreases colonic ammonia levels, increases the number of beneficial bacteria in the colon and improves an immune response, said composition comprising a combination of Arabinogalactan and Dihydroquercetin (taxifolin), wherein said Arabinogalactan is present in said combination as a fiber matrix in an amount higher than 70% as determined by weight on dry matter basis and said Dihydroquercetin is present in said fiber matrix. 
     
     
         10 . A composition for use in a human by oral administration to treat an abnormal inhibitory or excitory neuron function, said composition comprising a combination of Arabinogalactan and Dihydroquercetin (taxifolin), wherein said Arabinogalactan is present in said combination as a fiber matrix in an amount higher than 70% as determined by weight on dry matter basis and said Dihydroquercetin is present in said fiber matrix. 
     
     
         11 . A composition for use in a human by oral administration to treat one or more cardiometabolic disorders, said composition comprising a combination of Arabinogalactan and Dihydroquercetin (taxifolin), wherein said Arabinogalactan is present in said combination as a fiber matrix in an amount higher than 70% as determined by weight on dry matter basis and said Dihydroquercetin is present in said fiber matrix. 
     
     
         12 . A composition for use according to  claim 11  wherein said cardiometabolic disorders are selected from cardiovascular and metabolic syndrome disorders 
     
     
         13 . A composition for use according to  claim 12  wherein metabolic syndrome in a human is defined by at least three characteristics selected from:
 (a) a waist circumference greater than 102 cm for men and greater than 88 cm for women, 
 (b) a triglyceride level greater than 150 mg/dl, 
 (c) an HDL-cholesterol level less than 40 mg/dl for men and less than 50 mg/dl for women, 
 (d) a blood pressure greater than or equal to 130/85 mmHG, and 
 (e) a fasting glucose level greater than 110 mg/dl. 
 
     
     
         14 . A composition for use according to  claim 11  wherein said Arabinogalactan fiber matrix containing Dihydroquercetin is derived from a hardwood or coniferous wood of a  Larix  species and wherein said Arabinogalactan is Larch Arabinogalacatan. 
     
     
         15 . A composition for use according to  claim 14  wherein one gram of said Arabinogalactan has a capacity to inhibit lipid oxidation equivalent to at least 1,000 μmol Trolox Equivalent (TE)/gram based on an Oxygen Radical Absorbance Capacity (ORAC) value, wherein one gram of said. Arabinogalactan has an antioxidant capacity of Cell-based Antioxidant Protection (CAP-e) to protect live cells from oxidative damage to at least 6 CAP-e units per gram, where the CAP-e value is in Gallic Acid Equivalent (GAE) units: and wherein said antioxidant capacity is derived from natural constituents of said combination of said Arabinogalactan and said Dihydroquercetin but not from added antioxidants. 
     
     
         16 . A composition for use according to  claim 11  wherein said composition is a nutraceutical composition. 
     
     
         17 . A composition for use according to  claim 11  wherein said composition is a beverage. 
     
     
         18 . A composition for use according to  claim 11  wherein said composition is a nutritional bar. 
     
     
         19 . A composition for use according to  claim 11  wherein said composition is in a form of a tablet, a pill, a granule, a dragee, a capsule or an effervescent formulation.